The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ascletis Pharma's share price is $1.44.
Ascletis Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00. Hence, Ascletis Pharma's PS Ratio for today is .
The historical rank and industry rank for Ascletis Pharma's PS Ratio or its related term are showing as below:
ASCLF'
s PS Ratio Range Over the Past 10 Years
Min: 13.45 Med: 40.93 Max: 17740
Current: 5585
During the past 10 years, Ascletis Pharma's highest PS Ratio was 17740.00. The lowest was 13.45. And the median was 40.93.
ASCLF's PS Ratio is ranked worse than 99.14% of 930
companies
in the Biotechnology industry
Industry Median: 9.51
vs ASCLF: 5585.00
Ascletis Pharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Ascletis Pharma was 100.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -67.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -55.50% per year.
During the past 10 years, Ascletis Pharma's highest 3-Year average Revenue per Share Growth Rate was 77.00% per year. The lowest was -77.30% per year. And the median was -26.50% per year.
Back to Basics: PS Ratio
Ascletis Pharma (OTCPK:ASCLF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ascletis Pharma PS Ratio Related Terms
Ascletis Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ascletis Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ascletis Pharma's Share Price of today is $1.44.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
PS Ratio:
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
